PHASE II STUDY OF THE HISTONE-DEACIETYLASE INHIBITOR ITF2357 IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA PATIENTS

被引：0
|
作者：
Bonfante, V. [1 ]
Viviani, S. [1 ]
Fasola, C. [1 ]
Crippa, F. [1 ]
Marchiano, A. [1 ]
Valagussa, P. [1 ]
Gianni, A. M. [1 ]
机构：
[1] Ist Nazl Tumori, I-20133 Milan, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0605
引用
收藏
页码：244 / 244
页数：1
相关论文
共 50 条
  • [1] Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients
    Viviani, S.
    Bonfante, V.
    Fasola, C.
    Valagussa, P.
    Gianni, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL).
    Carlo-Stella, Carmelo
    Guidetti, Anna
    Viviani, Simonetta
    Bonfante, Valeria
    Valagussa, Pinuccia
    Marchiano, Alfonso
    Crippa, Flavio
    Zambelli, Stefania
    Fasola, Cinzia
    Corradini, Paolo
    Tarella, Corrado
    Di Nicola, Massimo
    Gianni, Alessandro M.
    BLOOD, 2008, 112 (11) : 896 - 897
  • [3] A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
    Monica Galli
    Silvia Salmoiraghi
    Joseé Golay
    Antonella Gozzini
    Claudia Crippa
    Norbert Pescosta
    Alessandro Rambaldi
    Annals of Hematology, 2010, 89 : 185 - 190
  • [4] A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
    Galli, Monica
    Salmoiraghi, Silvia
    Golay, Josee
    Gozzini, Antonella
    Crippa, Claudia
    Pescosta, Norbert
    Rambaldi, Alessandro
    ANNALS OF HEMATOLOGY, 2010, 89 (02) : 185 - 190
  • [5] A phase II multiple dose clinical trial of historic deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: Preliminary results
    Galli, Monica
    Salmoiraghi, Silvia
    Golay, Josee
    Gozzini, Antonella
    Bosi, Alberto
    Crippa, Claudia
    Rossi, Giuseppe
    Pescosta, Norbert
    Cortelazzo, Sergio
    Sechi, Alessandra
    Oldoni, Tiziano
    Rambaldi, Alessandro
    BLOOD, 2007, 110 (11) : 356A - 356A
  • [6] Decreased whole blood cytokine production during a phase I trial of the histone deacetylase inhibitor ITF2357
    Oldoni, Tiziano
    Furlan, Antonio
    Monzani, M. Valmen
    Dinarello, Charles A.
    CYTOKINE, 2009, 48 (1-2) : 120 - 120
  • [7] A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Fanale, M.
    Pro, B.
    McLaughlin, P.
    Neelapu, S.
    Fayad, L.
    Wedgwood, A.
    Dubay, M.
    Backstrom, J.
    Martell, R. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Histone deacetylase inhibitor ITF2357 is effective on the P39 cells. A gene expression study
    Petrini, M.
    Galimberti, S.
    Canestraro, M.
    Savli, H.
    Palumbo, G. A.
    Nagy, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma
    Ibrahim, D
    Smith, MR
    Varterasian, M
    Karanes, C
    Millenson, M
    Yeslow, G
    Pemberton, P
    Lai, P
    Abrams, J
    Al-Katib, A
    LEUKEMIA & LYMPHOMA, 2004, 45 (10) : 2079 - 2084
  • [10] Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma
    Moskowitz, Alison J.
    Hamlin, Paul A., Jr.
    Perales, Miguel-Angel
    Gerecitano, John
    Horwitz, Steven M.
    Matasar, Matthew J.
    Noy, Ariela
    Palomba, Maria Lia
    Portlock, Carol S.
    Straus, David J.
    Graustein, Tricia
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) : 456 - 460
12345